Clinical Trial Details
| Trial ID: | L0834 |
| Source ID: | NCT01533545 |
| Associated Drug: | Mepivacaine With Epinephrine |
| Title: | Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients |
| Acronym: | |
| Status: | TERMINATED |
| Study Results: | NO |
| Results: | |
| Conditions: | Renal Insufficiency, Chronic |
| Interventions: | DRUG: Mepivacaine with epinephrine|DRUG: Plain mepivacaine |
| Outcome Measures: | Primary: Plasma concentration of mepivacaine, 0, 5, 10, 20, 30, 45, 60, 120, and 180 min after blockade | Secondary: Central circulation, Heart rate, blood pressure, cardiac output, stroke volume, and systemic vascular resistance, 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, and 60 min after blockade|Peripheral tissue oxygenation, Near infrared spectrometry obtained from the triceps muscle of the blocked arm, 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, and 60 min after blockade|Cardiotoxicity of local anesthetic, 12-lead ECG, 0, 5, 10, 20, 30, 45, and 60 min after blockade|Neurotoxicity of local anesthetic, Visual and hearing disturbances, dysarthria, tingling, perioral numbness, dizziness, paraesthesia, muscular twitching and rigidity, Continuously for 1 hour after blockade |
| Sponsor/Collaborators: | Sponsor: Rigshospitalet, Denmark |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | |
| Enrollment: | 16 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT |
| Start Date: | 2012-09 |
| Completion Date: | 2014-09 |
| Results First Posted: | |
| Last Update Posted: | 2014-04-16 |
| Locations: | Rigshospitalet, Copenhagen, 2100, Denmark |
| URL: | https://clinicaltrials.gov/show/NCT01533545 |
